Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

KidneyIntelX data shows ability to assess risk

June 6, 2022
RNS Number : 6872N Renalytix PLC 06 June 2022   Renalytix plc ("Renalytix" or the "Company")   KidneyIntelX TM Demonstrates Ability to Assess Risk of Heart Failure Hospitalization and Death in Large International Diabetic Kidney Disease Patient Cohort   Data shared in oral presentation at American

Total Voting Rights

April 29, 2022
RNS Number : 9425J Renalytix PLC 29 April 2022   Renalytix plc   (" Renalytix " or the " Company ")     Total voting rights   NEW YORK and SALT LAKE CITY , 29 April, 2022 - Renalytix (LSE: RENX) announces that t he Company's total issued share capital consists of 74,760,432 shares of 0.25 pence

Grant of Share Options

April 22, 2022
RNS Number : 9726I Renalytix PLC 22 April 2022     Renalytix plc ("Renalytix" or the "Company")   Grant of Share Options   New York and SALT LAKE CITY , April  22, 2022   -   Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that its Remuneration Committee has agreed to issue options over a total

Issue of shares

April 8, 2022
RNS Number : 7218H Renalytix PLC 08 April 2022   Renalytix plc ("Renalytix" or the "Company")   Issue of shares   NEW YORK and SALT LAKE CITY , 8 April, 2022 - Renalytix Plc   (NASDAQ: RNLX) (LSE: RENX)   announces that under the Company's Employee Share Purchase Plan (the "ESPP"), 22,814 new

Successful completion of $30.0m financing package

April 8, 2022
RNS Number : 7737H Renalytix PLC 08 April 2022   NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES ,  CANADA ,  AUSTRALIA , JAPAN , THE REPUBLIC OF SOUTH AFRICA , NEW ZEALAND OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR

$30.0 million financing package

March 31, 2022
RNS Number : 7325G Renalytix PLC 31 March 2022   NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES ,  CANADA ,  AUSTRALIA , JAPAN , THE REPUBLIC OF SOUTH AFRICA , NEW ZEALAND OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR

Half-year Report

March 31, 2022
RNS Number : 6807G Renalytix PLC 31 March 2022       Renalytix plc ("Renalytix" or the "Company")   Half Year Report   LONDON and SALT LAKE CITY , March 31, 2022 - Renalytix plc (NASDAQ: RNLX) (LSE : RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing

Timothy Scannell appointed to the Board

March 30, 2022
RNS Number : 5577G Renalytix PLC 30 March 2022     Renalytix plc ("Renalytix" or the "Company")   Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors   NEW YORK and SALT LAKE CITY , March 30, 2022 - Renalytix Plc   (NASDAQ: RNLX) (LSE: RENX) announces that, following the

Enrollment Milestone for KidneyIntelX

March 29, 2022
RNS Number : 3159G Renalytix PLC 29 March 2022   Renalytix Reaches Enrollment Milestone for Building KidneyIntelX as Premier Precision Medicine Platform for Kidney Disease and Diabetes   KidneyIntelX RAPID biobank program and partners on track to reach over 30,000 biospecimens with matched

Notice of Results

March 25, 2022
RNS Number : 9571F Renalytix PLC 25 March 2022     Renalytix plc ("Renalytix" or the "Company")   Renalytix to Report Second Quarter and First Half Fiscal Year 2022 Financial Results on March 31   NEW YORK and SALT LAKE CITY , March 25, 2022 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today
Displaying 11 - 20 of 209